Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.31 |
| ▸ | IL1B | P01584 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14533705 | 1.00 | CYP1A2 (0.44) | CYP1A2CNR1CNR2KDM4EALDH1A1 | |
| SCHEMBL17835197 | 1.00 | CYP1A2 (0.44) | CYP1A2CNR1CNR2KDM4EALDH1A1 | |
| SCHEMBL17490615 | 1.00 | CYP1A2 (0.44) | CYP1A2CNR1CNR2KDM4EALDH1A1 | |
| SCHEMBL17835204 | 1.00 | CYP1A2 (0.44) | CYP1A2CNR1CNR2KDM4EALDH1A1 | |
| SCHEMBL17835224 | 1.00 | CYP1A2 (0.44) | CYP1A2CNR1CNR2KDM4EALDH1A1 | |
| SCHEMBL28195917 | 0.94 | CYP1A2 (0.39) | CYP1A2 | |
| SCHEMBL7097788 | 0.83 | CYP1A2 (0.42) | CYP1A2CNR1CNR2KDM4EALDH1A1 | |
| SCHEMBL16907745 | 0.83 | CYP1A2 (0.44) | CYP1A2KDM4EP2RX7IL1B | |
| SCHEMBL2034305 | 0.81 | CYP1A2 (0.43) | CYP1A2P2RX7IL1B | |
| SCHEMBL17310987 | 0.81 | CYP1A2 (0.43) | CYP1A2P2RX7IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016100281-A1 | INDOLE AND AZAINDOLES DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-23 | — | — | WO | disclosed |
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX3, P2RX7, P2RX2 | CYP1A2 1617/4885CNR1 69/4885CNR2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.